Uterine fibroids affect up to 40% of reproductive-age women. While many women may have no symptoms, others suffer with heavy menstrual bleeding, anemia, dysmenorrhea, pelvic pain and pressure, reduced quality of life, and reduced fertility. This is particularly true for Black women who are disproportionately affected. Communication is often lacking between women and their ob-gyns and PCPs regarding appropriate patient-centered treatments for their uterine fibroids. Join us as we explore keys to the early diagnosis of uterine fibroids and unravel the shared decision-making process that leads to maximizing patient outcomes.
New Directions in the Management of Uterine Fibroids
New Directions in the Management of Uterine Fibroids
CME/CE Broadcast Replay
22
- Host: William Mencia, MD, FACEHP, CHCP
- Guest: Stephen M. Cohen, MD, FACOG
- Guest: Sateria Venable
New thinking around the timing of uterine fibroid care and new medical options may be game changers for patients and their healthcare providers.
Available credits: 0.50
Time to complete: 30 minutes
Released:
Valid until:
Take Post-Test
If you’ve already completed the activity.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
William Mencia, MD, FACEHP, CHCP
Vice President, Scientific Affairs
Global Learning Collaborative
Fort Washington, PA
No relationships reported.Faculty:
Stephen M. Cohen, MD, FACOG
Faculty
SUNY Upstate Medical School
Syracuse, NY
Consulting Fees: AbbVieSateria Venable
Founder & CEO of The Fibroid Foundation
Bethesda, MD
No relationships reportedReviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose.
- Stephen Chavez has nothing to disclose.
- Barry A. Fiedel, PhD, has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Recognize the role of early diagnosis in improving outcomes for patients with uterine fibroids
- Formulate strategies to engage patients in discussions about their fibroid symptoms and treatment preferences
- Evaluate the latest evidence on medical therapies for the management of uterine fibroids
- Develop approaches to reduce implicit bias in developing care strategies for Black women with uterine fibroids
Target Audience
This activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, nurses, and certified nurse midwives in the fields of obstetrics and gynecology, family practice, and internal medicine.
Accreditation and Credit Designation Statements
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from AbbVie.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Prova Education and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education and Omnia Education, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments